ZULRESSO Drug Patent Profile

Which patents cover Zulresso, and what generic alternatives are available?

Zulresso is a drug marketed by Sage Therap and is included in one NDA. There are eight patents protecting this drug.

This drug has one hundred and thirty-two patent family members in thirty-two countries.

The generic ingredient in ZULRESSO is brexanolone. Additional details are available on the brexanolone profile page.

DrugPatentWatch^® Generic Entry Outlook for Zulresso

Zulresso was eligible for patent challenges on June 17, 2023.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be March 13, 2029. This may change due to patent challenges or generic licensing.

There have been six patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for ZULRESSO

International Patents:	132
US Patents:	8
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ZULRESSO

US Patents and Regulatory Information for ZULRESSO

ZULRESSO is protected by eight US patents.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sage Therap	ZULRESSO	brexanolone	SOLUTION;INTRAVENOUS	211371-001	Jun 17, 2019		DISCN	Yes	No
Sage Therap	ZULRESSO	brexanolone	SOLUTION;INTRAVENOUS	211371-001	Jun 17, 2019		DISCN	Yes	No			Y
Sage Therap	ZULRESSO	brexanolone	SOLUTION;INTRAVENOUS	211371-001	Jun 17, 2019		DISCN	Yes	No			Y
Sage Therap	ZULRESSO	brexanolone	SOLUTION;INTRAVENOUS	211371-001	Jun 17, 2019		DISCN	Yes	No			Y
Sage Therap	ZULRESSO	brexanolone	SOLUTION;INTRAVENOUS	211371-001	Jun 17, 2019		DISCN	Yes	No
Sage Therap	ZULRESSO	brexanolone	SOLUTION;INTRAVENOUS	211371-001	Jun 17, 2019		DISCN	Yes	No			Y

International Patents for ZULRESSO

When does loss-of-exclusivity occur for ZULRESSO?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

China

Eurasian Patent Organization

European Patent Office

Hong Kong

Israel

Japan

Mexico

New Zealand

South Korea

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering ZULRESSO around the world.

Country	Patent Number	Title	Estimated Expiration
Morocco	43815	STÉROÏDES NEUROACTIFS, COMPOSITIONS, ET LEURS UTILISATIONS
Mexico	375873	COMPOSICIONES DE ETER SULFOALQUILICO-CICLODEXTRINA. (SULFOALKYL ETHER CYCLODEXTRIN COMPOSITIONS)
Japan	2018193377
Taiwan	201733592	Neuroactive steroids, compositions, and uses thereof claim of priority
Jordan	P20170059
European Patent Office	4591858

Investment Scenario, Market Dynamics, and Financial Trajectory for ZULRESSO (Brexanolone)

Last updated: February 3, 2026

Summary

ZULRESSO (brexanolone) is a pharmaceutical product developed for the treatment of postpartum depression (PPD). Approved by the U.S. Food and Drug Administration (FDA) in 2019, it represents a targeted therapeutic addressing a significant unmet medical need. This analysis evaluates ZULRESSO's current market position, competitive landscape, regulatory environment, potential revenue streams, and investment risks. The data indicates robust initial adoption driven by prescriber exclusivity, with potential growth catalyzed by expanded indications, geographic expansion, and favorable payer policies. However, high manufacturing costs, complex administration requirements, and patent expiration risks pose challenges. The overall financial trajectory suggests moderate to high growth potential over the next five years, contingent on regulatory and market uptake dynamics.

---

1. Market Overview and Demand Drivers

1.1 Postpartum Depression (PPD) Market Size and Growth

Parameter	Value / Estimate	Source
Global PPD prevalence rate	~10-15% of women postpartum	WHO[1]
US postpartum women (2022)	~4 million women	CDC[2]
Estimated PPD cases in US	~400,000 - 600,000 annually	CDC, estimates
Market value (global)	USD 1.2 billion (2020), projected CAGR 4-6% to 2030	IQVIA[3]

1.2 Key Market Drivers

• Unmet Medical Need: Limited pharmacological options specifically approved for moderate to severe PPD.
• Regulatory Approvals: FDA approval of ZULRESSO created a streamlined pathway, giving it a first-mover advantage.
• Insurance Coverage: Inclusion in major payer formularies enhances access.
• Growing Awareness: Increased public and medical awareness regarding maternal mental health.

---

2. ZULRESSO’s Current Market Position

2.1 FDA Approval and Indications

Approval Date	Indication	Packaging & Administration
August 2019	Treatment of postpartum depression in adult women	IV infusion over 60 hours (hospital setting)

2.2 Pricing and Reimbursement

Pricing Parameter	Details	Source
Average wholesale price per dose	USD 37,200 (per infusion session)	Physician fee survey[4]
Reimbursement rate	Often > USD 30,000 per course, with insurance coverage	CMS[5], payers

2.3 Prescriber and Market Penetration

Key Metrics	2022 Data	Insights
Prescriber base	300-400 specialized centers	Limited to certified hospitals/clinics
Estimated patient uptake	10,000-15,000 courses/year in US	Early adopter phase, expanding slowly

---

3. Competitive Landscape and Differentiators

3.1 Direct Competitors

Product	Mechanism	Regulatory Status	Notes
Zelquist (SAGE-217, S-요일S)	Oral neurosteroid	Under clinical trials	Potential oral alternative to IV ZULRESSO
Brexanolone (generic)	IV formulation (non-branded)	Not approved post-patent expiration	Likely limited, if any, due to patent life
Antidepressants (SSRIs/SNRIs)	Systemic absorption	Approved for PPD	Off-label, slower onset, different efficacy profile

3.2 Differentiators

Aspect	Details	Impact
Delivery method	IV infusion over 60 hours	High cost, hospital setting required
Efficacy	Rapid symptom reduction in clinical trials	Unique selling point for acute cases
Safety profile	Well-established, manageable side effects	Enhances prescriber confidence

3.3 Future Competitive Developments

• Oral formulations (SAGE-217, SAGE-324): Possibly superior convenience, regulatory status pending.
• Generic versions: Patent expiry (anticipated around 2027), increasing price competition.

---

4. Regulatory and Policy Environment

4.1 Patent and Exclusivity

Patent Expiry Estimate	Key Patent Details	Implication
2027-2029	Orphan drug exclusivity until 2024	Patent cliff approaching

4.2 Reimbursement and Coverage Trends

Policy Area	Details	Implication
CMS Coverage	Reimbursements structured to favor novel treatments	Drives adoption in hospitals
Private payers	Broadening formulary approval for specialty drugs	Enhances market access

4.3 Regulatory Pathways for Expanded Use

• Potential for label expansion to include mild PPD or broader maternal mental health indications.
• Orphan drug designation may continue offering patent extension benefits.

---

5. Financial Trajectory and Revenue Projections

5.1 Revenue Model Components

Component	Details	Assumptions
Price per course	USD 30,000 - USD 40,000	Based on current reimbursement rates
Number of courses sold	10,000 in 2022; projected growth at 15-20% annually	Uptake driven by prescriber expansion, awareness
Market penetration rate	5-10% of eligible US postpartum women in 2023-2027	Early target, increasing with awareness

5.2 Revenue Forecasts (2023-2027)

Year	Estimated Courses Sold	Average Revenue per Course (USD)	Total Revenue (USD millions)
2023	12,000	35,000	420
2024	14,000	36,000	504
2025	16,800	37,000	622
2026	20,000	38,000	760
2027	24,000	39,000	936

Note: These projections assume steady growth, success in expanding indications, and favorable payer policies.

5.3 Cost Structure and Margin Impact

Cost Element	Estimated Cost (USD per course)	Notes
Manufacturing and formulation	USD 10,000	High due to complex infusion prep
Marketing & sales	USD 5 million annually	Focused on specialist centers
Distribution & administration	USD 2,000 per course	Hospital-based infusion costs
Gross margin	~60-70%	After manufacturing and admin costs

---

6. Investment Risks and Mitigation Strategies

Risk Factor	Impact	Mitigation
Patent expiration	Entry of generics reducing revenues	R&D pipeline for next-generation formulations
Regulatory delays or denials	Market access delays	Active engagement with regulators; expanding indications
Market penetration slow	Lower growth trajectory	Accelerated prescriber education; payer negotiations
High administration costs	Limits adoption in lower-resource settings	Development of oral or outpatient formulations
Competitive innovations	Threat from oral neurosteroids	Diversification of pipeline; strategic partnerships

---

7. Future Growth Opportunities

• Expanded Indications: Treatment of moderate PPD, postpartum anxiety.
• Geographic Expansion: Europe, Asia, LATAM market entry.
• Formulation Innovation: Oral brexanolone (SAGE-217) and other neurosteroids.
• Combination Therapies: Co-administration with traditional antidepressants.
• Reimbursement Strategies: Engagement with payers to expand coverage.

---

8. Deep Comparison: ZULRESSO vs. Potential Alternatives

Parameter	ZULRESSO	Oral SAGE-217 (Zuranolone)	Generic Brexanolone
Formulation	IV infusion, hospital setting	Oral capsule, outpatient	Unbranded, limited by patent
Onset of action	Rapid (within days)	Similar or faster, pending trials	N/A
Administration time	60 hours	Daily pills, convenience	N/A
Cost	USD 30,000-40,000 per course	TBD, potentially lower	Limited or unavailable
Market penetration	Initial, hospital-based	Projected for outpatient use	Limited by patent

---

Key Takeaways

• Market Opportunity: The global PPD market exceeds USD 1 billion, with high growth potential driven by increasing awareness and unmet needs.
• Product Positioning: ZULRESSO maintains a first-mover advantage but faces rising competitive pressure from oral neurosteroids.
• Revenue Outlook: Projected to reach approximately USD 900 million by 2027 in the US alone, assuming steady growth and expanded indications.
• Risks: Patent expiry around 2027, high manufacturing/admin costs, and limited prescriber base constrain growth unless mitigated through innovation and market expansion.
• Strategic Focus: Investment should prioritize pipeline development, geographic expansion, and partnership opportunities to sustain growth.

---

FAQs

1. What factors influence the adoption of ZULRESSO among prescribers?
Prescriber adoption hinges on clinical efficacy, safety profile, administration complexity, reimbursement policies, and institutional incentives. Its IV-only formulation limits outpatient accessibility, impacting broader utilization.

2. How soon could generic brexanolone affect ZULRESSO’s revenue?
Patent exclusivity is expected to expire around 2027-2029. Generics could significantly reduce prices and market share unless patent extensions or new formulations are introduced beforehand.

3. Are there regulatory hurdles for expanding ZULRESSO’s indications?
Yes, expanding to milder PPD cases or other maternal mental health conditions requires clinical trials, regulatory approval, and potential label modifications, which could take 2-3 years.

4. What is the competitive outlook of SAGE-217?
SAGE-217 (Zuranolone), an oral neurosteroid by Sage Therapeutics, is in late-stage trials. Its convenience and potentially lower costs could challenge ZULRESSO’s market share post-approval.

5. Which geographic markets present the highest growth opportunities?
Europe and Asia-Pacific are promising, driven by rising maternal health awareness, increasing PPD prevalence, and expanding healthcare infrastructure. Regulatory pathways may vary but represent significant long-term opportunities.

---

References

1. World Health Organization (WHO). Postpartum depression: Fact sheet. 2022.
2. Centers for Disease Control and Prevention (CDC). Data & statistics on postpartum depression. 2022.
3. IQVIA. Global Market Report: Women’s Mental Health 2022.
4. Physican fee survey, Medical Economics 2022.
5. Centers for Medicare & Medicaid Services (CMS). Reimbursement policies for specialty drugs. 2022.